Navicare Biotech Co., Ltd.
8472.TWO · TWO
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 331.55M | 280.10M | -53.45M | -82.68M | -4.66 |
| 2023 FY | 388.50M | 281.82M | -90.16M | -51.83M | -2.92 |
| 2024 FY | 337.03M | 211.87M | -76.78M | -78.46M | -4.41 |
| 2025 FY | 478.07M | 172.16M | -31.82M | -23.27M | -1.31 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 1.21B | 796.38M | 115.42M | 232.22M | 415.36M |
| 2023 FY | 1.18B | 818.89M | 86.31M | 248.84M | 363.53M |
| 2024 FY | 999.54M | 714.47M | 79.00M | 260.97M | 285.07M |
| 2025 FY | 1.05B | 779.12M | 159.19M | 327.47M | 270.50M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -68.41M | -406.21M | -474.62M | -9.76M | -20.90M |
| 2023 FY | -108.19M | -37.18M | -145.37M | — | -29.10M |
| 2024 FY | -63.49M | -8.73M | -72.22M | — | -7.32M |
| 2025 FY | -3.17M | -958.00K | -4.12M | — | 80.20M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 744.91M | 861.72M | — | — | — |
| 2023 FY | 656.71M | 819.24M | — | — | — |
| 2024 FY | 461.14M | 643.12M | — | — | — |
| 2025 FY | 1.27B | 1.43B | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 135.42M | 42.07M | -7.21M | -6.40M | -0.36 |
| 2025 Q3 | 133.69M | 42.20M | -6.41M | -2.63M | -0.15 |
| 2025 Q4 | 123.39M | 52.83M | -2.61M | 2.90M | 0.17 |
| 2026 Q1 | 122.83M | 41.50M | -7.86M | -4.67M | -0.26 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 1.05B | 776.56M | 191.04M | 339.97M | 269.23M |
| 2025 Q3 | 1.02B | 752.60M | 125.82M | 336.15M | 267.30M |
| 2025 Q4 | 1.05B | 779.12M | 159.19M | 327.47M | 270.50M |
| 2026 Q1 | 1.04B | 777.27M | 73.22M | 321.40M | 266.12M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -1.29M | — | -1.29M | — | 126.20M |
| 2025 Q3 | -38.00M | — | -38.00M | — | -65.22M |
| 2025 Q4 | 71.16M | -850.00K | 70.31M | — | 33.37M |
| 2026 Q1 | -28.64M | — | -28.64M | — | -87.55M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 515.72M | 664.64M | — | — | — |
| 2025 Q3 | 1.35B | 1.56B | — | — | — |
| 2025 Q4 | 1.25B | 1.42B | — | — | — |
| 2026 Q1 | 1.43B | 1.68B | — | — | — |